CORNYSESEC EDGAREDGAR

Cencora, Inc.

Wholesale-Drugs, Proprietaries & Druggists' Sundries·CONSHOHOCKEN, PA·FY end 09/30·CIK 1140859

Board of Directors

11 members · 10 independent · FY 2025
DirectorRoleTenureAgeCommitteesIndep.Annual fees
Werner BaumannDirector2y63AuditCompExecutive$383,095
Frank K. ClyburnDirector1y61RiskFinance$396,436
Ellen G. CooperDirector0y61
D. Mark DurcanChair10y64Executive$375,217
Lon R. GreenbergDirector12y75RiskExecutiveFinanceGovernance Sustainability and Corporate Responsibility$330,225
Lorence H. Kim, M.D.Director3y51CompExecutiveFinance$330,225
Robert P. MauchCEO and Director1y59Executive
Redonda G. Miller, M.D.Director2y59RiskExecutiveGovernance Sustainability and Corporate Responsibility$385,225
Dennis M. NallyDirector6y73AuditCompExecutive$345,706
Lori J. RyerkerkDirector1y63$192,390
Lauren M. TylerDirector2y64AuditGovernance Sustainability and Corporate Responsibility$360,940

Risk-factor diff

FY 2025 10-K vs. FY 2024
+70 new76 removed

Net-new paragraphs in the most recent 10-K's Item 1A. Companies rarely add risk language without a real reason — additions here are often a leading signal of management concerns.

NEW · FY 2025

Walgreens and Boots together accounted for approximately 25% of our revenue in fiscal 2025 and, as of September 30, 2025, accounted for approximately 38% of our accounts receivable, net. Evernorth Health Services accounted for approximately 13% of our revenue in fiscal 2025. Our top ten customers, including governmental agencies, represented approximately 66% of revenue in fiscal 2025. We have distributor relationships with GPOs in multiple distribution segments. We may lose a key customer or GPO relationship if any existing contract with such customer or GPO expires without being extended, re…

NEW · FY 2025

The anticipated ongoing benefits of our relationship with Walgreens and Boots may not be realized.

NEW · FY 2025

On August 28, 2025, Sycamore Partners, a private equity firm, acquired Walgreens Boots Alliance, Inc. (“WBA”). We have a distribution agreement in the U.S. pursuant to which we distribute pharmaceuticals to Walgreens pharmacies as well as a generics purchasing services arrangement under which Walgreens Boots Alliance Development GmbH (“WBAD”) provides a variety of services to us, including negotiating acquisition pricing with generic manufacturers on our behalf. Each of these agreements has a stated term that does not expire until 2029. We also have an international distribution agreement purs…

NEW · FY 2025

In addition, the processes needed to achieve and maintain the expected cost savings, growth initiatives and efficiencies in sourcing, logistics and distribution associated with our relationship with Walgreens and Boots are complex, costly, and time consuming. Achieving the anticipated benefits from the arrangements on an ongoing basis is subject to a number of significant challenges and uncertainties, including, without limitation: (i) the potential inability to realize and/or delays in realizing potential benefits resulting from participation in our generics purchasing services arrangement wi…

NEW · FY 2025

A disruption in our distribution or generic purchasing services arrangements with Walgreens or WBAD could adversely affect our business and financial results.

+ 25 more new paragraphs not shown

Policies & disclosures

Clawback, anti-hedging, stock ownership, and related-party policies will populate from extracted proxy sections.